会议资料 江苏亚虹医药科技股份有限公司 2024 年年度股东大会 二〇二五年五月 1 | 2024 年年度股东大会须知 3 | | | --- | --- | | 2024 年年度股东大会议程 5 | | | 议案一： 7 | | | 《关于公司<2024 年年度报告>及其摘要的议案》 | 7 | | 议案二： 8 | | | 《关于公司<2024 年度董事会工作报告>的议案》 | 8 | | 议案三： 25 | | | 《关于公司<2024 年度监事会工作报告>的议案》 | 25 | | 议案四： 28 | | | 《关于公司<2024 年度财务决算报告>的议案》 | 28 | | 议案五： 30 | | | 《关于公司 2024 年度利润分配方案的议案》 30 | | | 议案六： 31 | | | 《关于公司 年度董事薪酬（津贴）方案的议案》 31 2025 | | | 议案七： 32 | | | 《关于公司 2025 年度监事薪酬方案的议案》 32 | | | 议案八： 33 | | | 《关于续聘公司 2025 年度审计机构的议案》 33 | | | 议案九： 37 | | | 《关于确认募投项目部 ...

Core Viewpoint - The article discusses the disparity in employee compensation within the A-share pharmaceutical and biotechnology sector for the year 2024, highlighting the highest and lowest average salaries among companies in the industry. Group 1: Highest Average Salaries - The top ten companies with the highest average employee salaries in the pharmaceutical and biotechnology sector are predominantly innovative drug companies, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - The average salary of BeiGene's R&D personnel is 956,000 yuan, with domestic R&D personnel earning an average of 592,000 yuan and overseas R&D personnel earning 1,586,000 yuan [2] - Other companies in the top ten include Dizal Pharmaceutical (迪哲医药) with an average salary of 686,700 yuan and Yihong Pharmaceutical (亚虹医药) with an average salary of 627,400 yuan [2][3] Group 2: Lowest Average Salaries - The ten companies with the lowest average salaries in the sector have an average salary as low as 70,500 yuan, with the lowest being 70,500 yuan at Yisheng Pharmaceutical (益盛药业) [7][9] - The majority of these low-salary companies are traditional Chinese medicine firms and offline pharmacy businesses, with four being Chinese medicine companies [10] - Companies like Teva Pharmaceutical (特一药业) reported a significant decline in net profit, leading to a 10.1% decrease in average salary compared to 2023 [11] Group 3: Salary Trends and Industry Insights - Among the 498 companies in the pharmaceutical and biotechnology sector, 49 companies have an average salary above 300,000 yuan, while 144 companies fall between 200,000 to 300,000 yuan [8] - The article notes that the average salary for most innovative drug companies has increased compared to 2023, with the highest increase being 13.62% for Ailisi (艾力斯) [6] - The article also highlights the challenges faced by offline pharmacies, with a significant drop in customer traffic and profitability due to changes in healthcare policies and increased competition [11][12]

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-017 江苏亚虹医药科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 23 日10 点 00 分 召开地点：上海市浦东新区高科西路 551 号万信酒店一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 23 日 至2025 年 5 月 23 日 1 （七） 涉及公开征集股东投票权 无 股东大会召开日期：2025年5月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系 ...

Revenue Performance - The company's revenue for Q1 2025 reached ¥61,101,125.72, representing a 151.24% increase compared to ¥24,319,537.45 in the same period last year[4] - Total revenue for Q1 2025 reached RMB 61,101,125.72, a significant increase from RMB 24,319,537.45 in Q1 2024, representing a growth of approximately 151.5%[16] - Total operating revenue for Q1 2025 was 61,061,157.83 RMB, significantly up from 26,465,560.01 RMB in Q1 2024, representing an increase of about 130.8%[20] - The company attributed the revenue increase primarily to higher sales volumes of Pazopanib tablets and Nilotinib tablets during the reporting period[6] Profitability - The net profit attributable to shareholders was -¥83,530,738.28, slightly worse than -¥82,848,207.86 in the previous year[4] - In Q1 2025, the company reported a net profit of -86,341,679.22 RMB, compared to -82,969,385.29 RMB in Q1 2024, indicating a year-over-year decline of approximately 4.1%[17] - The company’s total comprehensive income for Q1 2025 was -86,393,882.94 RMB, compared to -84,084,642.90 RMB in Q1 2024, reflecting a decline of about 2.7%[18] - The basic earnings per share remained at -¥0.15, unchanged from the previous year[4] - The basic earnings per share for Q1 2025 remained at -0.15 RMB, consistent with Q1 2024[18] Research and Development - R&D expenses totaled ¥55,061,232.76, a decrease of 19.15% from ¥68,099,878.30 year-on-year, with R&D expenses accounting for 90.11% of revenue[4] - Research and development expenses for Q1 2025 were 55,061,232.76 RMB, down from 68,099,878.30 RMB in Q1 2024, indicating a reduction of approximately 19.1%[17] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥110,357,157.61, an improvement from -¥129,110,035.08 in the same period last year[4] - The company's operating cash flow for Q1 2025 was -110,357,157.61 RMB, an improvement from -129,110,035.08 RMB in Q1 2024[21] - Cash and cash equivalents as of March 31, 2025, amounted to RMB 871,264,190.39, up from RMB 628,197,162.91 as of December 31, 2024, reflecting a growth of approximately 38.7%[12] - Cash and cash equivalents at the end of Q1 2025 totaled 865,579,055.99 RMB, an increase from 775,167,766.25 RMB at the end of Q1 2024[21] Assets and Liabilities - The company's total assets decreased by 2.76% to ¥2,161,563,230.97 from ¥2,222,991,903.79 at the end of the previous year[5] - Total assets decreased to RMB 2,161,563,230.97 as of March 31, 2025, from RMB 2,222,991,903.79 at the end of 2024, a decline of about 2.8%[14] - The equity attributable to shareholders decreased by 3.99% to ¥1,890,799,054.31 from ¥1,969,405,336.09 at the end of the previous year[5] - The company's equity attributable to shareholders decreased to RMB 1,890,799,054.31 as of March 31, 2025, from RMB 1,969,405,336.09 at the end of 2024, a decline of about 4.0%[14] - Total liabilities increased to RMB 272,307,481.81 as of March 31, 2025, compared to RMB 252,618,105.29 at the end of 2024, indicating an increase of approximately 7.8%[14] Other Financial Metrics - The company reported a total of ¥5,821,474.77 in non-recurring gains and losses for the period[6] - The company held 8,667,675 shares in its repurchase account, accounting for 1.52% of total shares as of the reporting period[10] - The company did not report any changes in the participation of major shareholders in the securities lending business[11] - The company reported a tax expense of -49,563.51 RMB in Q1 2025, compared to -343,675.93 RMB in Q1 2024, indicating a reduction in tax liabilities[17] - Investment activities generated a net cash flow of 319,563,507.59 RMB in Q1 2025, compared to 554,416,433.51 RMB in Q1 2024, showing a decrease of approximately 42.4%[21]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688176 证券简称：亚虹医药 公告编号：2025-016 江苏亚虹医药科技股份有限公司 关于参加2024年度科创板创新药行业集体业绩说明会 暨2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年5月8日（星期四）15:00 - 17:00 ● 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心视频结合网络互动 ● 投资者可于2025年4月28日（星期一）至5月07日（星期三）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱securities@asieris.cn进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 江苏亚虹医药科技股份有限公司（以下简称"公司"）已于2025年4月19日发布公司2024年年度报告，并 将于2025年4月30日发布公司2025年第一 ...

Group 1: Yishitong - Yishitong has made progress in several new material projects, including solid oxide battery (SOC) systems, high-purity quartz sand, bismuth stone, thermally conductive spherical alumina, and flame-retardant materials [1] - The SOC system project is progressing as planned, with the single battery pilot line operating stably, and the stack pilot production line expected to be completed by 2025 [1] - High-purity quartz sand's technical indicators and performance optimization have been completed, with plans to test in a single crystal factory by 2025 and establish a thousand-ton pilot line [1] - Bismuth stone shipments are expected to increase in 2024, with a slight decrease in price, and significant shipment growth anticipated in Q1 2025 [1] - The sales revenue of ceramic flame-retardant materials is increasing, with plans to expand into more application scenarios [1] Group 2: Desay Battery - Desay Battery anticipates uncertainties in the macroeconomic environment but aims to explore new markets and businesses for performance growth [2] - In 2024, revenue from smartphone battery business is expected to decline by 10.39%, influenced by both volume and price [2] - In Q1 2025, revenue from smartphone batteries is projected to grow by 8.97%, while wearable device batteries are expected to increase by 15.79% [2] - Revenue from electric tools, smart home, and mobility businesses is expected to grow by 24.37%, while energy storage business revenue is projected to decline by 14.86% [2] - The company plans to continue expanding production capacity in Vietnam, with expected revenue growth in Vietnam to double compared to last year [2] Group 3: Yahui Pharmaceutical - Yahui Pharmaceutical has made progress in the approval and commercialization of APL-1702, with the listing application accepted and review underway [3] - APL-2501 has completed multiple experiments, with IND submission expected by mid-2026, showing strong clinical competitive potential [3] - The company is targeting patients with strong willingness to pay for the initial positioning of Haikewei, gradually promoting blue light cystoscopy technology as a standard solution [3] - APL-2302 shows good pharmacokinetic characteristics and significant anti-tumor effects, having entered clinical research [3] - The company expects rapid revenue growth in 2024 and plans to upgrade its commercialization system in 2025, including hiring a Chief Commercial Officer and optimizing the organizational structure [3]

上海兆天投资管理有限公司成立于2015年2月，由范迪钊先生发起设立，公司注册在上海市静安区，注 册及实收资本为人民币1000万元，办公地址为上海市浦东新区浦明路1500号万得大厦12楼。公司为中国 证券投资基金业协会观察会员，并拥有投资顾问资格。公司主要从事权益类私募证券投资基金的投资管 理，投资品种覆盖A股、港股、美股，以科技成长策略为主。团队核心成员来自于公募基金，平均拥有 20年+证券从业经验，公司创始人曾荣获一年期、三年期、五年期金牛奖。公司成立以来，已与工商银 行、招商银行、中信证券、中金公司、鹏华基金、南华期货、银河证券、银河资本、国泰君安、安信证 券、国海证券等金融机构建立了紧密的合作关系。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。 调研纪要：亚虹医药介绍了APL-1702的审批和商业化进展，已获上市申请受理并推进审评审批，启动 商业化准备工作，海外开发计划达成一致。APL-2501完成多项实验，预计2026年中期递交IND，具有较 强的临床竞争潜力。海克威初期定位支付意愿强的患者群体，逐步推动蓝光膀胱镜技术成为标 ...

亚虹医药 2025042120250416 摘要 • 亚虹医药通过股票回购和高管增持提振信心，实现商业化盈亏平衡，派特 尔和爱迪特表现突出。创新药 APL1,702 已申报上市，正全力推进获批， 有望成为新的增长点。 • 公司已转型为初具规模的生物医药商业化公司，拥有近 400 名员工，商业 化团队约 180 人，研发团队约 160 人。在美国加州设立研发中心，专注 于 ADC 产品开发，并引入多位高管加强商业化和业务拓展能力。 • 亚虹医药积极拥抱 AI 技术，建立靶向 AI 驱动的 drug discovery 平台，用 于小分子创新药物开发，并结合计算机辅助设计（CADD）提升研发效率， 已在 USP1 和 FGFR23 抑制剂项目上取得显著进展。 • 公司在 ADC 领域采取孵化策略，致力于开发 best-in-class ADC、双载体 ADC 以及结合免疫疗法的 ADC，已拥有亲水性 linker 专利及高效侧向偶 联技术，其中 CLDN6 ADC 展现独特特色。 • 亚虹医药在光动力技术方面取得突破，1,702 西维他治疗宫颈癌前病变临 床试验表现优秀，正在中国进行新药上市审评。同时，与华东理工 ...

2025年4月19日，亚虹医药(688176.SH)发布2024年年度报告。截至2025年4月18日，共有72个机构投资 者披露持有亚虹医药A股股份，合计持股量达1.45亿股，占亚虹医药总股本的25.43%。其中，前十大机 构投资者包括Pan-Scientific Holdings Co., Ltd.、北京龙磐健康医疗投资中心(有限合伙)、泰州东虹企业 管理中心(有限合伙)、深圳国中中小企业发展私募股权投资基金合伙企业(有限合伙)、泰州亚虹企业管 理中心(有限合伙)、杭州凯泰民德投资合伙企业(有限合伙)、宁波开投瀚润投资管理合伙企业(有限合 伙)-宁波瀚海乾元股权投资基金合伙企业(有限合伙)、上海上汽恒旭投资管理有限公司-嘉兴尚颀颀恒昕 投资合伙企业(有限合伙)、上海弘信股权投资基金管理有限公司-国联科金(平潭)股权投资合伙企业(有限 合伙)、中国农业银行股份有限公司-鹏华医药科技股票型证券投资基金，前十大机构投资者合计持股比 例达21.92%。相较于上一季度，前十大机构持股比例合计下跌了0.05个百分点。 公募基金方面本期较上一季度持股减少的公募基金共计2个，包括景顺长城中证1000指数增强A、万家 医药量 ...